Public health value of fixed-dose combinations in hypertension.
It is well documented that reducing blood pressure (BP) in hypertensive individuals reduces the risk of cardiovascular (CV) events. Despite this, many patients with hypertension remain untreated or inadequately treated, and fail to reach the recommended BP goals. Suboptimal BP control, whilst arising from multiple causes, is often due to poor patient compliance and/or persistence, and results in a significant health and economic burden on society. The use of fixed-dose combinations (FDCs) for the treatment of hypertension has the potential to increase patient compliance and persistence. When compared with antihypertensive monotherapies, FDCs may also offer equivalent or better efficacy, and the same or improved tolerability. As a result, FDCs have the potential to reduce both the CV event rates and the non-drug healthcare costs associated with hypertension. When FDCs are adopted for the treatment of hypertension, issues relating to copayment, formulary restrictions and therapeutic reference pricing must be addressed.
Ruilope
Luis M
LM
Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain. ruilope@ad-hocbox.com
Burnier
Michel
M
Muszbek
Noemi
N
Brown
Ruth E
RE
Keskinaslan
Abdulkadir
A
Ferber
Philippe
P
Harms
Günter
G
D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000191:economics; D017281:Cost of Illness; D004338:Drug Combinations; D016527:Drug Costs; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D007349:Insurance, Health, Reimbursement; D010349:Patient Compliance; D011634:Public Health
D000959:Antihypertensive Agents; D004338:Drug Combinations